|
Real-time Estimate
Cboe BZX
11:08:26 2026-11-18 EST
|
5-day change | 1st Jan Change | ||
| 3.190 USD | +8.14% |
|
+0.64% | -16.31% |
| 11-17 | SAB Biotherapeutics, Inc. Presents at UBS Global Biopharma Conference 2026, Nov-17-2026 08:40 AM | |
| 11-06 | SAB Biotherapeutics' Pivotal Diabetes Trial Data Could Drive Shares, UBS Says | MT |
| Market Cap | 266M 241M 223M 201M 380M 24.83B 394M 2.69B 1.06B 13.4B 997M 976M 42.33B | P/E 2026 * |
-3.08x | P/E 2027 * | -4.13x |
|---|---|---|---|---|---|
| Enterprise Value | -6.64M -6.03M -5.57M -5.02M -9.48M -620M -9.84M -67.07M -26.53M -335M -24.9M -24.38M -1.06B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | -458x |
| Free-Float |
96.2% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| SABS | Delayed | |
| SABS | Real-time |
Last Transcript: SAB Biotherapeutics, Inc.
| 1 day | +7.80% | ||
| 1 week | +0.64% | ||
| Current month | -6.57% | ||
| 1 month | +20.38% | ||
| 3 months | -17.41% | ||
| 6 months | -12.08% | ||
| Current year | -16.31% |
| 1 week | 2.85 | 3.22 | |
| 1 month | 2.44 | 3.4 | |
| Current year | 2.44 | 5.15 | |
| 1 year | 2.44 | 5.15 | |
| 3 years | 1 | 9.72 | |
| 5 years | 1 | 120.9 | |
| 10 years | 1 | 129 |
| Manager | Title | Age | Since |
|---|---|---|---|
Eddie Sullivan
CEO | Chief Executive Officer | 60 | 2014-06-30 |
Samuel Reich
CEO | Chief Executive Officer | 51 | 2024-02-01 |
Lucy To
DFI | Director of Finance/CFO | 40 | 2024-08-11 |
| Director | Title | Age | Since |
|---|---|---|---|
Samuel Reich
CHM | Chairman | 51 | 2021-10-21 |
William Polvino
BRD | Director/Board Member | 65 | 2019-10-21 |
David Link
BRD | Director/Board Member | 70 | 2021-10-21 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/17/26 | Tax | Chief Technology Officer | -473 | 0.0006% | ||
| 3/24/26 | Tax | Chief Technology Officer | 988 | 0.0021% | ||
| 2/5/26 | Free | Chief Executive Officer | 4,800,000 | 10.0826% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +8.14% | +0.64% | -19.95% | -62.46% | 266M | ||
| -1.34% | -4.12% | +53.70% | +68.83% | 66.37B | ||
| +1.08% | -1.26% | +9.61% | +91.79% | 58.86B | ||
| +0.68% | +0.54% | +26.08% | +86.79% | 55.22B | ||
| -2.25% | -4.07% | +10.71% | +114.45% | 47.21B | ||
| -0.71% | -6.95% | +17.56% | +24.43% | 42.45B | ||
| -2.58% | +2.22% | +14.73% | +41.28% | 36.44B | ||
| -1.85% | -11.72% | +126.01% | +634.08% | 35.19B | ||
| -0.17% | -1.94% | +82.25% | +57.30% | 32.66B | ||
| -1.43% | -1.37% | -40.93% | +383.73% | 26.73B | ||
| Average | -0.07% | -3.00% | +27.98% | +144.02% | 40B | |
| Weighted average by Cap. | -0.80% | -2.92% | +33.33% | +142.33% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 62.5K 56.74K 52.41K 47.28K 89.26K 5.84M 92.68K 632K 250K 3.15M 234K 230K 9.96M |
| Net income | -89.89M -81.6M -75.38M -68.01M -128M -8.4B -133M -908M -359M -4.53B -337M -330M -14.32B | -104M -94.5M -87.3M -78.75M -149M -9.73B -154M -1.05B -416M -5.25B -391M -382M -16.58B |
| Net Debt | -272M -247M -228M -206M -389M -25.45B -404M -2.75B -1.09B -13.73B -1.02B -1B -43.39B | -294M -267M -247M -223M -420M -27.5B -437M -2.97B -1.18B -14.84B -1.1B -1.08B -46.89B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-11-18 | US$3.115 | +5.59% | 113,905 |
| 26-11-17 | US$2.950 | -1.67% | 368,267 |
| 26-11-16 | US$3.000 | +1.35% | 388,165 |
| 26-11-13 | US$2.960 | -3.90% | 658,118 |
| 26-11-12 | US$3.080 | -0.96% | 2,111,559 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- SABS Stock
Select your edition
All financial news and data tailored to specific country editions
















